<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02182232</url>
  </required_header>
  <id_info>
    <org_study_id>1199.5</org_study_id>
    <nct_id>NCT02182232</nct_id>
  </id_info>
  <brief_title>A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer</brief_title>
  <official_title>A Phase I Open Label Dose Escalation Study of Continuous Oral Treatment With BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objectives of this trial were to determine the MTD of BIBF 1120 in combination&#xD;
      with carboplatin and paclitaxel, pharmacokinetics and objective response of treatment&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and intensity of adverse events according to Common Terminology Criteria for Adverse Events (version 3.0) associated with increasing doses of BIBF 1120</measure>
    <time_frame>up to day 126</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of BIBF 1120 in combination with carboplatin and paclitaxel</measure>
    <time_frame>up to day 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pre-dose plasma concentration (Cpre)</measure>
    <time_frame>up to day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response according to response evaluation criteria in solid tumors (RECIST)</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from best response to onset of tumor progression</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from start of treatment to time of documented tumor progression</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the curve (AUC) from 0 to 12 hours (AUC0-12)</measure>
    <time_frame>up to day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from 0 to the last quantifiable drug concentration (AUC0-tz)</measure>
    <time_frame>up to day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>up to day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration (tmax)</measure>
    <time_frame>up to day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate constant (λz) for BIBF 1120</measure>
    <time_frame>up to day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from 0 to 24 hours (AUC0-24) for paclitaxel</measure>
    <time_frame>up to day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from 0 extrapolated to 48 hours (AUC0-48) for paclitaxel</measure>
    <time_frame>up to day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from 0 extrapolated to infinity (AUC0-∞)</measure>
    <time_frame>up to day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of AUC0-∞ that is obtained by extrapolation (% AUCtz-∞)</measure>
    <time_frame>up to day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2)</measure>
    <time_frame>up to day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time after intravenous administration (MRTiv) for paclitaxel and carboplatin</measure>
    <time_frame>up to day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Clearance (CL/F)</measure>
    <time_frame>up to day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution during the terminal phase (Vz)</measure>
    <time_frame>up to day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from 0 to 24 hours (AUC0-24) for carboplatin</measure>
    <time_frame>Day 1 and 22 in the treatment time</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration 21 hours after start of infusion (C21) for carboplatin</measure>
    <time_frame>up to day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration 24 hours after start of infusion (C24) for paclitaxel</measure>
    <time_frame>up to day 42</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>BIBF 1120 with paclitaxel and carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BIBF 1120 monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBF 1120</intervention_name>
    <arm_group_label>BIBF 1120 with paclitaxel and carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>BIBF 1120 with paclitaxel and carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>BIBF 1120 monotherapy</arm_group_label>
    <arm_group_label>BIBF 1120 with paclitaxel and carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients with histologically or cytologically confirmed Stage IIIB&#xD;
             (including pleural effusion), IV or recurrent NSCLC&#xD;
&#xD;
          2. Bi-dimensionally measurable disease by one or more techniques (CT, MRI, X-ray)&#xD;
&#xD;
          3. Age 18 years or older&#xD;
&#xD;
          4. Life expectancy of at least three (3) months&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1&#xD;
&#xD;
          6. Written informed consent that is consistent with ICH-GCP guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment for NSCLC including chemotherapy, biologic response modifier therapy,&#xD;
             or any investigational drug&#xD;
&#xD;
          2. Participation in another clinical study within the past four weeks before start of&#xD;
             therapy or concomitantly with this study&#xD;
&#xD;
          3. Active brain metastases (stable for &lt;28 days, symptomatic, or requiring concurrent&#xD;
             steroids or antiepileptic therapy)&#xD;
&#xD;
          4. Centrally located tumors with radiologic evidence (CT or MRI) of local invasion of&#xD;
             major blood vessels&#xD;
&#xD;
          5. Cavitary or necrotic tumors&#xD;
&#xD;
          6. Sanguinous pleural effusion due to disease or pericardial effusion suspicious for&#xD;
             disease&#xD;
&#xD;
          7. Radiotherapy to an area of measurable disease (unless disease progression had been&#xD;
             documented following completion of therapy)&#xD;
&#xD;
          8. Radiotherapy within 4 weeks preceding Day 0&#xD;
&#xD;
          9. Other active malignancy diagnosed within the past 3 years (other than non-melanomatous&#xD;
             skin cancer)&#xD;
&#xD;
         10. Gastrointestinal abnormalities that would interfere with intake or absorption of the&#xD;
             study drug, such as a requirement for intravenous alimentation, prior surgical&#xD;
             procedures affecting absorption, treatment for peptic ulcer disease within the last 6&#xD;
             months, active gastrointestinal bleeding unrelated to cancer (as evidenced by either&#xD;
             hematemesis, hematochezia, or melena in the past 3 months and without endoscopic&#xD;
             documented resolution), or malabsorption syndromes&#xD;
&#xD;
         11. Significant cardiovascular disease (i.e., uncontrolled hypertension, myocardial&#xD;
             infarction within 6 months, unstable angina, serious cardiac arrhythmia, ≥NYHA Grade 2&#xD;
             congestive heart failure)&#xD;
&#xD;
         12. History of hemorrhagic or thrombotic event (including transient ischemic attacks) in&#xD;
             the past 12 months&#xD;
&#xD;
         13. Clinically significant hemoptysis (1 teaspoon or more) in the past 3 months&#xD;
&#xD;
         14. Concurrent therapeutic anticoagulation (except heparin flush as needed for maintenance&#xD;
             of an indwelling intravenous device) or antiplatelet therapy (except chronic low-dose&#xD;
             daily aspirin &lt;325 mg)&#xD;
&#xD;
         15. Known hypersensitivity to paclitaxel, carboplatin, or any of their excipients&#xD;
             including Cremophor® (polyoxyethylated castor oil)&#xD;
&#xD;
         16. Absolute neutrophil count (ANC) ≤1,500/μl, platelet count ≤100,000/μl, or hemoglobin&#xD;
             &lt;9 gm/dL&#xD;
&#xD;
         17. Total bilirubin &gt;1.5 mg/dL (26 μmol/L, SI Unit equivalent), alanine amino transferase&#xD;
             (ALT) and/or aspartate amino transferase (AST) ≥1.5 X ULN,&#xD;
&#xD;
         18. Serum creatinine &gt;1.5 mg/dL (&gt;132 μmol/L, SI Unit equivalent)&#xD;
&#xD;
         19. Persistent hematuria or proteinuria (more than trace)&#xD;
&#xD;
         20. Women and men who are sexually active and unwilling to use a medically acceptable&#xD;
             method of contraception&#xD;
&#xD;
         21. Pregnancy or breastfeeding&#xD;
&#xD;
         22. Known or suspected active alcohol or drug abuse&#xD;
&#xD;
         23. Patients unable to comply with the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>July 2, 2014</study_first_submitted>
  <study_first_submitted_qc>July 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 17, 2014</last_update_submitted>
  <last_update_submitted_qc>July 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

